R
Richard S.E. Keefe
Researcher at Duke University
Publications - 387
Citations - 40456
Richard S.E. Keefe is an academic researcher from Duke University. The author has contributed to research in topics: Cognition & Schizophrenia. The author has an hindex of 91, co-authored 373 publications receiving 36878 citations. Previous affiliations of Richard S.E. Keefe include Veterans Health Administration & King's College London.
Papers
More filters
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity
Keith H. Nuechterlein,Michael F. Green,Robert S. Kern,Lyle E. Baade,M Deanna,Jonathan D. Cohen,Susan M. Essock,Wayne S. Fenton,Frederick J. Frese,James M. Gold,Terry E. Goldberg,Robert K. Heaton,Richard S.E. Keefe,Helena C. Kraemer,Raquelle I. Mesholam-Gately,Larry J. Seidman,Ellen Stover,Daniel R. Weinberger,Alexander S. Young,Steven Zalcman,Stephen R. Marder +20 more
TL;DR: The MATRICS Consensus Cognitive Battery is expected to be the standard tool for assessing cognitive change in clinical trials of cognition-enhancing drugs for schizophrenia and may also aid evaluation of cognitive remediation strategies.
Journal ArticleDOI
Persistent cannabis users show neuropsychological decline from childhood to midlife
Madeline H. Meier,Avshalom Caspi,Antony Ambler,Antony Ambler,Hona Lee Harrington,Renate Houts,Richard S.E. Keefe,Kay McDonald,Aimee L. Ward,Richie Poulton,Terrie E. Moffitt +10 more
TL;DR: Persistent cannabis use was associated with neuropsychological decline broadly across domains of functioning, even after controlling for years of education and cessation of cannabis use, suggestive of a neurotoxic effect of cannabis on the adolescent brain.
Journal ArticleDOI
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
Richard S.E. Keefe,Terry E. Goldberg,Philip D. Harvey,James M. Gold,Margaret P. Poe,Leigh Coughenour +5 more
TL;DR: The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer and to be highly correlated with the standard battery composite scores in patients and healthy controls.
Journal ArticleDOI
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Richard S.E. Keefe,Robert M. Bilder,Sonia M. Davis,Philip D. Harvey,Barton W. Palmer,James M. Gold,Herbert Y. Meltzer,Michael F. Green,George Capuano,T. Scott Stroup,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Clarence E. Davis,John K. Hsiao,Jeffrey A. Lieberman +16 more
TL;DR: After 2 months of antipsychotic treatment, all groups had a small but significant improvement in neurocognition, and after 18 months of treatment, neurocognitive improvement was greater in the perphenazine group than in the olanzapine and risperidone groups.